Treatment Strategies in ESR1-mut ER+/HER2- Breast Cancer: Practical Insights for Optimal Outcomes

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in patients with metastatic breast cancer, particularly as a mechanism of resistance to aromatase inhibitor treatment.

Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than relying on archival tissue testing.

Panelists discuss the EMERALD trial data, which shows the effectiveness of elacestrant in patients with estrogen receptor 1 (ESR1) mutations, particularly those who were on first-line CDK 4/6 inhibitors for longer than a year.

Panelists discuss the safety profile and adverse effects of elacestrant, highlighting its relatively mild nausea and ease of administration compared with other endocrine therapies.

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's performance in actual clinical practice even exceeded the promising results from the clinical trial.

Panelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.